Pandemic influenza A virus vaccines - CSL/NIAID
Alternative Names: Focetria (Mock-up); Foclivia; Influenza A virus H5N1/H9N2 subtypes vaccine - CSL/NIAIDLatest Information Update: 29 Apr 2021
At a glance
- Originator National Institute of Allergy and Infectious Diseases; Novartis
- Developer CSL
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Influenza A virus H5N1 subtype; Influenza A virus infections
Most Recent Events
- 23 Mar 2021 Seqirus entered manufacturing and supply agreement with Government of Canada for influenza vaccine
- 23 Mar 2021 Registered for Influenza A virus H5N1 subtype (Prevention) in Canada (Parenteral)
- 13 Jan 2010 Interim immunogenicity data from a clinical study in patients with end-stage renal disease released by SciCLone and Sigma-Tau